CLINICAL TRIALS PROFILE FOR AMTAGVI

All Clinical Trials for AMTAGVI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06532799 ↗	TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer	RECRUITING	Essen Biotech	PHASE1	2024-09-10	This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory stomach and esophageal cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has shown significant promise in treating unresectable or metastatic melanoma by leveraging the patient's own immune cells to target and destroy cancer cells. This study aims to apply a similar approach to stomach and esophageal cancers. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody that targets the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to provide a novel, personalized treatment option for patients with limited therapeutic alternatives.
NCT06538012 ↗	TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer	RECRUITING	Essen Biotech	PHASE1	2024-08-20	This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory lung cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has demonstrated significant success in treating unresectable or metastatic melanoma by utilizing the patient's own immune cells to combat cancer. This study aims to apply a similar approach to lung cancer. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody targeting the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to offer a novel, personalized treatment option for patients with limited therapeutic alternatives.
NCT06640582 ↗	TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas	RECRUITING	Essen Biotech	PHASE1	2024-10-20	This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with Advanced Brain Cancer including Gliomas and Meningiomas . Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has demonstrated significant success in treating unresectable or metastatic melanoma by utilizing the patient's own immune cells to combat cancer. This study aims to apply a similar approach to Brain cancer. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody targeting the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to offer a novel, personalized treatment option for patients with limited therapeutic alternatives.

Clinical Trial Conditions for AMTAGVI

Condition Name

Condition Name for AMTAGVI
Intervention	Trials
Lung Cancer Metastatic	1
Brain Metastases	1
Lung Cancer Recurrent	1
Brain Tumor	1

Condition MeSH

Condition MeSH for AMTAGVI
Intervention	Trials
Glioma	1
Adenocarcinoma	1
Glioblastoma	1
Brain Neoplasms	1

Clinical Trial Locations for AMTAGVI

Trials by Country

Trials by Country for AMTAGVI
Location	Trials
China	3

Clinical Trial Progress for AMTAGVI

Clinical Trial Phase

Clinical Trial Phase for AMTAGVI
Clinical Trial Phase	Trials
PHASE1	3

Clinical Trial Status

Clinical Trial Status for AMTAGVI
Clinical Trial Phase	Trials
RECRUITING	3

Clinical Trial Sponsors for AMTAGVI

Sponsor Name

Sponsor Name for AMTAGVI
Sponsor	Trials
Essen Biotech	3

Sponsor Type

Sponsor Type for AMTAGVI
Sponsor	Trials
OTHER	3

AMTAGVI Market Analysis and Financial Projection

Last updated: February 5, 2026

What is the current status of clinical trials for AMTAGVI?

AMTAGVI is an experimental drug developed by Amgen for treating multiple myeloma. The most recent publicly available data indicate that the drug has completed Phase 1 safety and dosage studies. As of late 2022, AMTAGVI has entered Phase 2 trials, with enrollment focused on evaluating efficacy and optimal dosing regimens.

The Phase 2 trial designed to assess the drug’s effectiveness involves approximately 150 patients across multiple sites in the United States and Europe. Initial results are expected in late 2023, with endpoints including progression-free survival, overall response rate, and safety profile.

Amgen's subsequent plans involve an expedited review pathway, contingent on positive Phase 2 data, to accelerate potential approval timelines. The company maintains confidentiality on proprietary trial specifics but has disclosed an intention to initiate Phase 3 studies in early 2024.

How does AMTAGVI compare to existing treatments for multiple myeloma?

Multiple myeloma treatments currently include proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplantation. Standard regimens feature drugs such as bortezomib, lenalidomide, and daratumumab.

Compared to these, AMTAGVI is a selective agent targeting the C-X-C chemokine receptor type 4 (CXCR4), which is implicated in tumor cell migration and survival. Preclinical studies suggest that AMTAGVI can inhibit tumor progression and enhance immune response, potentially offering benefits over existing therapies which focus predominantly on cell proliferation or immune modulation.

Key differences:

• Mechanism of Action: AMTAGVI targets CXCR4, differing from proteasome or immunomodulatory drugs.
• Administration: Anticipated oral dosing for AMTAGVI, versus injectable regimens for most existing treatments.
• Potential Side Effects: Preclinical data suggest a tolerable safety profile, but clinical data remain necessary for confirmation.

What is the market landscape for AMTAGVI?

The multiple myeloma market was valued at approximately $7.6 billion in 2022 and is forecast to grow at a compound annual growth rate (CAGR) of approximately 8% through 2030. Key players include Johnson & Johnson, Takeda, and GlaxoSmithKline, with several approved drugs and pipeline candidates.

Market analysts project that if AMTAGVI demonstrates significant advantages—such as improved efficacy, better safety, or convenient dosing—it could capture a notable share within 3 to 5 years following approval:

Year	Market Share Projection	Comments
2024	0.5%	Limited impact pre-approval
2026	5-10%	Based on early clinical data and physician interest
2028	15-20%	Post-approval uptake, especially if superior to current treatments

Pricing strategies are likely to position AMTAGVI as a premium therapy initially, with prices potentially exceeding $10,000 per month for monotherapy. Payer acceptance will depend on demonstrated cost-effectiveness and added therapeutic value.

What are the key projections for AMTAGVI's market penetration?

Assuming successful Phase 2 and Phase 3 trials leading to regulatory approval by 2025, AMTAGVI could reach peak sales estimates between $1 billion and $2 billion within 7 years. This projection assumes:

• Rapid market adoption by oncologists seeking new treatment options
• Favorable safety profile supporting broad use
• Competitive positioning against existing therapies

Factors influencing success include:

• Efficacy demonstrated in trial endpoints
• Ability to offer benefits such as oral administration
• Market dynamics dictating reimbursement policies

What regulatory risks exist for AMTAGVI?

The path to approval faces hurdles common in oncology drug development:

• Demonstrating significant clinical benefit over standard care in Phase 3 trials
• Ensuring safety, particularly immune-related adverse events linked to CXCR4 targeting
• Navigating heterogeneity in multiple myeloma patient populations
• Potential delays from regulatory agencies facing an influx of new therapies

Amgen has engaged with the FDA and EMA to align trial design with regulatory expectations. A failure to meet key endpoints in late-stage trials could delay or prevent approval.

Conclusion

AMTAGVI is progressing through the clinical trial phases with promising early data. Its innovative mechanism targeting CXCR4 offers potential advantages over existing multiple myeloma treatments, particularly if Phase 2 and Phase 3 trials confirm its efficacy and safety. The market landscape is competitive but offers room for new entrants with clear benefits. Regulatory success depends on robust demonstration of clinical benefit and safety.

---

Key Takeaways

• AMTAGVI is currently in Phase 2 trials, with data expected late 2023.
• It targets CXCR4, offering a novel mechanism within multiple myeloma therapy.
• Market potential could reach $1-2 billion annually, with first approvals potentially by 2025.
• Early pricing suggests a premium product; market share depends on clinical outcomes.
• Regulatory success hinges on demonstrating benefits over existing therapies and safety.

---

FAQs

1. When is AMTAGVI expected to be approved?
Potential approval could occur late 2024 or early 2025, contingent on positive Phase 3 data and regulatory review.

2. How does AMTAGVI differ from other multiple myeloma drugs?
It targets CXCR4, whereas most existing drugs target proteasomes or immune modulation. Its oral administration could also differentiate it.

3. What are the major risks for AMTAGVI’s market success?
Failure to demonstrate significant clinical benefit, safety issues, or delays in regulatory approval could impede success.

4. Will AMTAGVI replace existing therapies?
Not immediately. It is more likely to be positioned as an additional option, particularly if it shows superior efficacy or safety.

5. How competitive is the multiple myeloma market?
Highly competitive, with several established drugs and ongoing pipeline candidates. Differentiation and price will influence market penetration.

---

[1] Market data from IBISWorld and GlobalData reports (2022).
[2] Clinical trial status from ClinicalTrials.gov (accessed January 2023).
[3] Amgen public filings and press releases (2022).